---
title: "QSAM Biosciences, Inc. (QSAM.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/QSAM.US.md"
symbol: "QSAM.US"
name: "QSAM Biosciences, Inc."
industry: "Biotechnology"
---

# QSAM Biosciences, Inc. (QSAM.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |

## Company Profile

QSAM Biosciences, Inc. engages in developing various nuclear medicines for the treatment of cancer. The company is involved in the development of CycloSam (Samaium-153 DOTMP), a clinical-stage bone targeting radiopharmaceutical. It has a license agreement with IGL Pharma, Inc.

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| Dividend Yield | 0.00% | - | - | - | - |

## References

- [Company Overview](https://longbridge.com/en/quote/QSAM.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/QSAM.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/QSAM.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
